Nahdi profit dips 8% to SAR 820.7M in 2024; Q4 at SAR 157.9M

Nahdi Medical Co. reported a net profit of SAR 820.7 million for 2024, an 8% decline from SAR 892.6 million a year earlier.

Financials (M)

Item	2023	2024	Change‬
Revenues	8,713.68	9,446.40	8.4 %
Gross Income	3,522.20	3,532.90	0.3 %
Operating Income	961.00	873.20	(9.1 %)
Net Income	892.62	820.70	(8.1 %)
Average Shares	130.00	130.00	-
Earnings Per Share before unusual items	6.62	6.06	(8.4 %)
EPS (Riyals)	6.87	6.31	(8.1 %)

Operating expenses increased by SAR 103.9 million reflecting the company’s ongoing investment in various strategic initiatives that include new openings, healthcare acceleration, UAE expansion and digitalization. However, the company improved its operating expenses as a percentage of revenue by 1.2%, reaching 28.5% in 2024. Additionally, other operating revenue edged higher.

Consequently, the company’s operating profit reached SAR 873.2 million, a decrease of SAR 87.8 million year-on-year (YoY).

Revenue grew 8.4% YoY to SAR 9.44 billion, driven by 6.5% growth in the retail business, investments in its digital capabilities, network expansion and commitment to providing competitive value to patients. Healthcare and UAE businesses nearly doubled revenue for the third consecutive year, with increases of 98.3% and 132.6%, respectively.

Gross profit rose by SAR 10.6 million to SAR 3.5 billion in 2024. The company noted that the gross profit in 2023 included a non-recurring inventory provisions release of SAR 33 million due to a change in the inventory provision policy.

Zakat charges decreased by SAR 37.8 million, mainly due to a one-time provision release of SAR 32.7 million following the closure of Zakat assessments for previous years.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2023	Q4 2024	Change‬
Revenues	2,214.25	2,363.00	6.7 %
Gross Income	853.76	882.40	3.4 %
Operating Income	185.00	192.30	3.9 %
Net Income	170.52	157.90	(7.4 %)
Average Shares	130.00	130.00	-
Earnings Per Share before unusual items	1.31	1.21	(7.4 %)
EPS (Riyals)	1.31	1.21	(7.4 %)

Item	Q3 2024	Q4 2024	Change‬
Revenues	2,353.25	2,363.00	0.4 %
Gross Income	850.98	882.40	3.7 %
Operating Income	175.80	192.30	9.4 %
Net Income	182.19	157.90	(13.3 %)
Average Shares	130.00	130.00	-
Earnings Per Share before unusual items	1.15	1.21	5.6 %
EPS (Riyals)	1.40	1.21	(13.3 %)

Q4 2024 net earnings slipped 7% YoY to SAR 157.9 million, as operating expenses increased by 3.8%. Moreover, there was an increase of SAR 17.6 million in the items below operating profit, mainly in financial charges to support the revenue growth, along with an increase of SAR 2.4 million in Zakat accruals.

On a sequential basis, net profit slumped 13.3% from SAR 182.19 million in Q3 2024.

Total shareholders’ equity, no minority interest, stood at SAR 2.58 billion by Dec. 31, 2024, compared to SAR 2.46 billion a year earlier.

Attached Documents

View more financial results

Quarterly Actuals vs Estimates 09/03/202510/03/2025

All
Above Expectations
Below Expectations

Company	Estimated	Actual	Change
SACO	(13.80)	3.42	124.8 %
JAHEZ	61.00	65.14	6.8 %
NAHDI	175.11	157.90	(9.8 %)

Company	Estimated	Actual	Change
SACO	(13.80)	3.42	124.8 %
JAHEZ	61.00	65.14	6.8 %

Company	Estimated	Actual	Change
NAHDI	175.11	157.90	(9.8 %)

Share Price

Nahdi Medical Co. (NAHDI)

	Current
Market Cap (M Riyal)	15,054.00
Enterprise Value (EV) (M)	14,306.35
Shares Outstanding ((M))	130.00
EPS ( Riyal) (TTM)	6.31
Book Value (BV) ( Riyal)	19.89
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	19.10
P/E (TTM)	18.34
Price/book	5.82
Return on Average Assets (%) (TTM)	14.5
Return on Average Equity (%) (TTM)	32.5

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	Earnings Per Share before unusual items
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	721.24	-	5.55	-	721.24	5.55
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	610.65	(15.3 %)	4.70	(34.25)	644.91	4.96
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	692.00	13.3 %	5.32	-	692.00	5.32
Q1 2020	315.77	-	2.43	-	315.77	2.43
Q2 2020	268.73	-	2.07	-	268.73	2.07
Q3 2020	97.81	-	0.75	-	97.81	0.75
Q4 2020	166.81	-	1.28	18.00	148.81	1.14
2020	849.12	22.7 %	6.53	18.00	831.12	6.39
Q1 2021	195.02	(38.2 %)	1.50	-	195.02	1.50
Q2 2021	226.83	(15.6 %)	1.74	-	226.83	1.74
Q3 2021	247.45	153.0 %	1.90	-	247.45	1.90
Q4 2021	143.23	(14.1 %)	1.10	6.70	136.54	1.05
2021	812.53	(4.3 %)	6.25	6.70	805.83	6.20
Q1 2022	237.51	21.8 %	1.83	-	237.51	1.83
Q2 2022	268.51	18.4 %	2.07	-	268.51	2.07
Q3 2022	253.81	2.6 %	1.95	2.06	251.75	1.94
Q4 2022	127.99	(10.6 %)	0.98	(1.55)	129.53	1.00
2022	887.81	9.3 %	6.83	0.51	887.30	6.83
Q1 2023	244.34	2.9 %	1.88	-	244.34	1.88
Q2 2023	264.95	(1.3 %)	2.04	-	264.95	2.04
Q3 2023	212.81	(16.2 %)	1.64	32.04	180.76	1.39
Q4 2023	170.52	33.2 %	1.31	-	170.52	1.31
2023	892.62	0.5 %	6.87	32.04	860.58	6.62
Q1 2024	232.95	(4.7 %)	1.79	-	232.95	1.79
Q2 2024	247.74	(6.5 %)	1.91	-	247.74	1.91
Q3 2024	182.19	(14.4 %)	1.40	32.70	149.49	1.15
Q4 2024	157.90	(7.4 %)	1.21	-	157.90	1.21
2024	820.70	(8.1 %)	6.31	32.70	788.00	6.06

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	Earnings Per Share before unusual items
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	721.24	-	5.55	-	721.24	5.55
2018	610.65	(15.3 %)	4.70	(34.25)	644.91	4.96
2019	692.00	13.3 %	5.32	-	692.00	5.32
2020	849.12	22.7 %	6.53	18.00	831.12	6.39
2021	812.53	(4.3 %)	6.25	6.70	805.83	6.20
2022	887.81	9.3 %	6.83	0.51	887.30	6.83
2023	892.62	0.5 %	6.87	32.04	860.58	6.62
2024	820.70	(8.1 %)	6.31	32.70	788.00	6.06

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	7,056.42	-	2,096.30	-	756.79	-
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	7,350.00	4.2 %	2,073.86	(1.1 %)	666.28	(12.0 %)
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	7,824.67	6.5 %	2,463.71	18.8 %	801.29	20.3 %
Q1 2020	2,096.94	-	759.19	-	327.66	-
Q2 2020	2,423.57	-	946.98	-	301.33	-
Q3 2020	2,135.55	-	778.23	-	112.45	-
Q4 2020	1,986.14	-	765.27	-	183.65	-
2020	8,642.21	10.4 %	3,249.67	31.9 %	925.09	15.5 %
Q1 2021	1,981.11	(5.5 %)	779.71	2.7 %	224.35	(31.5 %)
Q2 2021	2,070.14	(14.6 %)	859.97	(9.2 %)	255.14	(15.3 %)
Q3 2021	2,041.74	(4.4 %)	857.80	10.2 %	268.95	139.2 %
Q4 2021	1,973.23	(0.7 %)	807.21	5.5 %	99.44	(45.9 %)
2021	8,066.22	(6.7 %)	3,304.68	1.7 %	847.88	(8.3 %)
Q1 2022	2,079.49	5.0 %	851.73	9.2 %	255.15	13.7 %
Q2 2022	2,239.47	8.2 %	926.30	7.7 %	300.00	17.6 %
Q3 2022	2,158.98	5.7 %	911.06	6.2 %	271.48	0.9 %
Q4 2022	2,138.24	8.4 %	856.31	6.1 %	148.89	49.7 %
2022	8,616.19	6.8 %	3,545.39	7.3 %	975.52	15.1 %
Q1 2023	2,105.04	1.2 %	889.20	4.4 %	260.20	2.0 %
Q2 2023	2,231.49	(0.4 %)	900.35	(2.8 %)	271.15	(9.6 %)
Q3 2023	2,162.90	0.2 %	846.89	(7.0 %)	195.15	(28.1 %)
Q4 2023	2,214.25	3.6 %	853.76	(0.3 %)	185.00	24.3 %
2023	8,713.68	1.1 %	3,522.20	(0.7 %)	961.00	(1.5 %)
Q1 2024	2,257.50	7.2 %	860.83	(3.2 %)	223.20	(14.2 %)
Q2 2024	2,472.66	10.8 %	938.68	4.3 %	267.58	(1.3 %)
Q3 2024	2,353.25	8.8 %	850.98	0.5 %	175.80	(9.9 %)
Q4 2024	2,363.00	6.7 %	882.40	3.4 %	192.30	3.9 %
2024	9,446.40	8.4 %	3,532.90	0.3 %	873.20	(9.1 %)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	7,056.42	-	2,096.30	-	756.79	-
2018	7,350.00	4.2 %	2,073.86	(1.1 %)	666.28	(12.0 %)
2019	7,824.67	6.5 %	2,463.71	18.8 %	801.29	20.3 %
2020	8,642.21	10.4 %	3,249.67	31.9 %	925.09	15.5 %
2021	8,066.22	(6.7 %)	3,304.68	1.7 %	847.88	(8.3 %)
2022	8,616.19	6.8 %	3,545.39	7.3 %	975.52	15.1 %
2023	8,713.68	1.1 %	3,522.20	(0.7 %)	961.00	(1.5 %)
2024	9,446.40	8.4 %	3,532.90	0.3 %	873.20	(9.1 %)

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	29.71 %	12.66 %	10.22 %
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
2018	28.22 %	11.01 %	8.77 %
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
2019	31.49 %	16.57 %	8.84 %
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	37.60 %	13.58 %	9.62 %
2020	37.60 %	16.57 %	9.62 %
Q1 2021	38.35 %	14.17 %	8.33 %
Q2 2021	38.95 %	15.99 %	8.18 %
Q3 2021	40.38 %	18.24 %	10.13 %
Q4 2021	40.97 %	17.60 %	9.99 %
2021	40.97 %	17.60 %	9.99 %
Q1 2022	41.36 %	17.85 %	10.39 %
Q2 2022	41.31 %	18.03 %	10.68 %
Q3 2022	41.37 %	17.96 %	10.58 %
Q4 2022	41.15 %	18.25 %	10.30 %
2022	41.15 %	18.25 %	10.30 %
Q1 2023	41.46 %	18.40 %	10.35 %
Q2 2023	41.20 %	18.13 %	10.32 %
Q3 2023	40.44 %	17.18 %	9.49 %
Q4 2023	40.05 %	17.55 %	9.88 %
2023	40.42 %	18.12 %	9.88 %
Q1 2024	39.05 %	16.89 %	9.58 %
Q2 2024	38.43 %	16.69 %	9.14 %
Q3 2024	37.69 %	16.38 %	8.61 %
Q4 2024	37.40 %	-	8.34 %
2024	37.40 %	-	8.34 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2015	-	-	-
2016	-	-	-
2017	29.71 %	12.66 %	10.22 %
2018	28.22 %	11.01 %	8.77 %
2019	31.49 %	16.57 %	8.84 %
2020	37.60 %	16.57 %	9.62 %
2021	40.97 %	17.60 %	9.99 %
2022	41.15 %	18.25 %	10.30 %
2023	40.42 %	18.12 %	9.88 %
2024	37.40 %	-	8.34 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	36.20 %	-	15.06 %
Q2 2020	39.07 %	-	11.09 %
Q3 2020	36.44 %	11.57 %	4.58 %
Q4 2020	38.53 %	14.99 %	7.49 %
Q1 2021	39.36 %	18.26 %	9.84 %
Q2 2021	41.54 %	19.34 %	10.96 %
Q3 2021	42.01 %	20.26 %	12.12 %
Q4 2021	40.91 %	12.35 %	6.92 %
Q1 2022	40.96 %	19.23 %	11.42 %
Q2 2022	41.36 %	19.88 %	11.99 %
Q3 2022	42.20 %	19.86 %	11.66 %
Q4 2022	40.05 %	13.96 %	6.06 %
Q1 2023	42.24 %	19.83 %	11.61 %
Q2 2023	40.35 %	18.84 %	11.87 %
Q3 2023	39.16 %	16.08 %	8.36 %
Q4 2023	38.56 %	15.53 %	7.70 %
Q1 2024	38.13 %	17.06 %	10.32 %
Q2 2024	37.96 %	17.90 %	10.02 %
Q3 2024	36.16 %	14.91 %	6.35 %
Q4 2024	37.34 %	-	6.68 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	-	-	-	-
Q2 2018	-	-	-	-
Q3 2018	-	-	-	-
Q4 2018	-	-	-	-
Q1 2019	-	-	-	-
Q2 2019	-	-	-	-
Q3 2019	-	-	-	-
Q4 2019	-	-	-	-
Q1 2020	130.00	-	-	-
Q2 2020	130.00	-	-	-
Q3 2020	130.00	-	-	-
Q4 2020	130.00	6.53	6.39	15.99
Q1 2021	130.00	5.60	5.46	17.49
Q2 2021	130.00	5.28	5.14	15.54
Q3 2021	130.00	6.43	6.29	11.26
Q4 2021	130.00	6.25	6.20	12.34
Q1 2022	130.00	6.58	6.53	14.15
Q2 2022	130.00	6.90	6.85	16.49
Q3 2022	130.00	6.95	6.88	16.15
Q4 2022	130.00	6.83	6.83	17.26
Q1 2023	130.00	6.88	6.88	16.05
Q2 2023	130.00	6.85	6.85	18.29
Q3 2023	130.00	6.54	6.30	17.51
Q4 2023	130.00	6.87	6.62	18.94
Q1 2024	130.00	6.78	6.53	17.82
Q2 2024	130.00	6.65	6.40	19.83
Q3 2024	130.00	6.41	6.16	18.53
Q4 2024	130.00	6.31	6.06	19.89

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2015	-	-	-	-
2016	-	-	-	-
2017	130.00	5.55	5.55	12.52
2018	130.00	4.70	4.96	12.91
2019	130.00	5.32	5.32	13.73
2020	130.00	6.53	6.39	15.99
2021	130.00	6.25	6.20	12.34
2022	130.00	6.83	6.83	17.26
2023	130.00	6.87	6.62	18.94
2024	130.00	6.31	6.06	19.89

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	23.57	23.75	10.95
Q2 2022	23.46	23.63	9.81
Q3 2022	27.32	27.59	11.75
Q4 2022	24.48	24.50	9.69
Q1 2023	26.82	26.84	11.50
Q2 2023	24.80	24.82	9.29
Q3 2023	22.05	22.87	8.24
Q4 2023	19.95	20.70	7.23
Q1 2024	21.69	22.50	8.25
Q2 2024	19.83	20.59	6.65
Q3 2024	20.53	21.37	7.10
Q4 2024	18.63	19.40	5.91

Period	P/E	Adjusted P/E	Price/book
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	-	-	-
2021	-	-	-
2022	24.48	24.50	9.69
2023	19.95	20.70	7.23
2024	18.63	19.40	5.91

Business Segments (Million)

Compared With The

Period	Front Shop	Pharma	Other
Q3 2020	1,149.16	983.85	2.54
Q4 2020	1,061.26	923.31	1.57
Q1 2021	1,065.84	913.56	1.71
Q2 2021	1,135.41	924.12	10.61
Q3 2021	1,081.26	950.21	10.27
Q4 2021	1,016.84	944.85	11.54
Q1 2022	1,017.79	1,044.51	17.20
Q2 2022	1,138.04	1,085.84	15.58
Q3 2022	1,114.55	1,026.61	17.82
Q4 2022	1,008.13	1,106.09	24.02
Q1 2023	988.58	1,081.66	34.79
Q2 2023	1,121.79	1,071.67	38.02
Q3 2023	1,034.23	1,085.11	43.56
Q4 2023	985.27	1,173.29	55.70
Q1 2024	981.17	1,198.88	77.44
Q2 2024	1,089.15	1,298.46	85.05
Q3 2024	950.24	1,311.97	91.04

Period	Front Shop	Pharma	Other
2020	4,797.40	3,839.44	5.37
2021	4,299.34	3,732.74	34.13
2022	4,278.50	4,263.06	74.63
2023	4,129.87	4,411.73	172.07

Analysts Estimates (Million)

Item	Q4 2024 (e)	Q4 2024 (a)	Change‬
Average	175.11	157.90	(9.8 %)

Estimates vs Actual (Million)

Item	Q4 2024 (e)	Q4 2024 (a)	Change
Riyad Capital	157.00	157.90	0.6 %
SNB Capital	167.00	157.90	(5.4) %
OSOOL AND BAKHEET	171.42	157.90	(7.9) %
United Securities Company	205.00	157.90	(23.0) %

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Nahdi profit dips 8% to SAR 820.7M in 2024; Q4 at SAR 157.9M

Financials (M)

Current Quarter Comparison (M)

Quarterly Actuals vs Estimates 09/03/202510/03/2025

View other reports

Share Price

Nahdi Medical Co. (NAHDI)

Financial Ratios

Profit Performance (Million)

Profit Performance (Million)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2024 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Nahdi profit dips 8% to SAR 820.7M in 2024; Q4 at SAR 157.9M

Content Summary:

Comments Analysis:

Financials (M)

Current Quarter Comparison (M)

Quarterly Actuals vs Estimates 09/03/202510/03/2025

View other reports

Share Price

Nahdi Medical Co. (NAHDI)

Financial Ratios

Profit Performance (Million)

Profit Performance (Million)

Financial results (Million)

Financial results (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2024

Revenue by Business Segment (Latest) 2024 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Business Segments (Million)